Skip to main content
OpenTrials
Completed

NCT Number: NCT00718744

Standardization of Chortoglyphus Arcuatus Allergenic Extract. Determination of Biological Activity in HEP Units

The main purpose of the trial is to prove the therapeutic value of the product and enable an effective and safe dosage schedule to be recommended

Completed

Looking for future studies?

Notify Me

Key information

About this study

The skin testing procedure, based on the Nordic Guidelines is the reference method for the biological calibration of in-House Reference Preparations (IHRP). The method is not intended for routine testing of allergen extracts. The use of this procedure is the basis for the definition of biological activity units: "the activity of an allergen extract is 10,000 Biological Units (BU) per ml (10 HEP per ml), when the extract provokes an specific skin reaction in the median sensitive patient with a wheal of the same size as a wheal provoked by a positive reference solution consisting of histamine 54.3 mmol/l (for example histamine dihydrochloride 10 mg/ml), when both solutions are administrated using the same technique (prick testing) on at least 20 individuals who are clinically allergic and cutaneously reactive to the allergen concerned".

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Voluntarily signed informed consent form by the patient
  • Patients should live in a geographic zone where allergy caused by Chortoglyphus arcuatus is a relevant problem.
  • Patients should not be excluded due to low or high sensitivity to the allergen, when they otherwise fulfil the inclusion criteria.
  • A positive case history with inhalant allergy related to exposure to the allergen to be tested.
  • A positive prick test (mean wheal diameter > 3 mm) when tested with a standardized extract prepared from the allergen source in question and/or a positive test for specific IgE.
  • A mean wheal diameter > 7 mm2 obtained in a prick test with histamine dihydrochloride 10 mg/ml.
  • Age: 18-50 years.
  • Both genders

Exclusion criteria

  • Immunotherapy in the past 2 years with an allergen preparation known to interfere with the allergens to be tested.
  • Use of drugs that may interfere with the skin reactions.
  • Pregnancy
  • Dermographism
  • Atopic dermatitis (locally at the test site)
  • Urticaria.

Treatment and study plan

Standardization of allergenic extract (Ch. arcuatus)

Other

Allergenic extract for cutaneous prick-test

Primary outcomes

  1. Wheal size area (mm2) of the immediate phase reaction.

    Time frame: 30 minutes per subject

Sponsors and collaborators

Lead sponsor

Laboratorios Leti, S.L.

Industry

Registry information

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Jul 21, 2008
Registry last updated
Aug 5, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.